Detalles de la búsqueda
1.
The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological Disease.
Cerebellum
; 22(4): 531-533, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35881322
2.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
N Engl J Med
; 370(4): 322-33, 2014 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24450891
3.
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
J Neurol Neurosurg Psychiatry
; 87(1): 106-12, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25669746
4.
Continuous event monitoring via a Bayesian predictive approach.
Pharm Stat
; 15(2): 109-22, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26643012
5.
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.
Alzheimers Dement
; 12(5): 623-30, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27017906
6.
Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: results from 3 randomized, double-blind placebo-controlled trials.
Pain Pract
; 14(4): 332-42, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23692321
7.
Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial.
Neurol Clin Pract
; 14(2): e200265, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38585443
8.
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.
Alzheimers Dement
; 9(2): 123-131.e1, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23411394
9.
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Alzheimers Dement
; 9(4): 438-44, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23809364
10.
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
N Engl J Med
; 370(15): 1460, 2014 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24724181
11.
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Alzheimers Dement
; 7(4): 367-85, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21784348
12.
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.
JAMA Neurol
; 78(3): 293-301, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33464300
13.
The pathway to secondary prevention of Alzheimer's disease.
Alzheimers Dement (N Y)
; 6(1): e12069, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32885024
14.
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Alzheimers Res Ther
; 12(1): 58, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32410694
15.
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease.
Clin Pharmacol Drug Dev
; 8(3): 326-335, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29920980
16.
Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.
Curr Alzheimer Res
; 15(13): 1231-1243, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30129411
17.
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.
J Alzheimers Dis
; 66(4): 1409-1424, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412493
18.
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Neurology
; 90(10): e877-e886, 2018 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29429971
19.
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.
J Alzheimers Dis
; 64(3): 689-707, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29914022
20.
Magnetic resonance imaging predictors of cognition in mild cognitive impairment.
Arch Neurol
; 64(7): 1023-8, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17620494